Daily Ards Research Analysis
Analyzed 16 papers and selected 3 impactful papers.
Summary
Mechanistic and translational advances in acute respiratory distress syndrome (ARDS) highlight new targets and care considerations. A FASEB Journal study identifies a GATA3–BMP9–Smad1/5–YAP axis that suppresses ferroptosis in sepsis-associated ARDS, while an ovine experiment demonstrates that selective hemoadsorption of cytokines and platelet–neutrophil complexes mitigates lung hyperpermeability. A large propensity score-weighted cohort suggests invasive mechanical ventilation is independently associated with higher mortality in COVID-19-related ARDS, underscoring careful patient selection and strict lung-protective strategies.
Research Themes
- Transcriptional and signaling control of ferroptosis in sepsis-related ARDS
- Extracorporeal hemoadsorption targeting platelet–neutrophil complexes and cytokines
- Causal inference on invasive mechanical ventilation in COVID-19 ARDS
Selected Articles
1. Transcription Factor GATA3 Ameliorates Sepsis-Associated Acute Respiratory Distress Syndrome by Activating Smad1/5-YAP Pathway via BMP9.
Using LPS-induced murine and alveolar epithelial cell models, the authors show that GATA3 transcriptionally activates BMP9, which in turn engages Smad1/5–YAP signaling to suppress inflammation and ferroptosis, alleviating sepsis-associated ARDS phenotypes. Pharmacologic (LDN193189) and genetic disruption of Smad1/5 or YAP abrogated BMP9’s protection, establishing a causal pathway.
Impact: This work delineates a previously unappreciated GATA3–BMP9–Smad1/5–YAP axis controlling ferroptosis in sepsis-related lung injury, offering testable targets for ARDS modulation. The multi-level validation enhances translational promise.
Clinical Implications: Although preclinical, targeting the GATA3–BMP9–Smad1/5–YAP pathway or ferroptosis could inspire novel adjunctive therapies for sepsis-associated ARDS, guiding biomarker development (BMP9, p-Smad1/5, YAP) and drug repurposing strategies.
Key Findings
- GATA3 binds and activates the BMP9 promoter, increasing BMP9 expression in lung epithelial cells.
- BMP9 overexpression activates Smad1/5–YAP signaling and reduces inflammation, oxidative stress, and ferroptosis in LPS-induced ARDS models.
- LDN193189 or knockdown of Smad1/5 or YAP attenuates BMP9’s protective effects, confirming pathway dependence.
Methodological Strengths
- Multi-modal validation across in vivo (murine) and in vitro (MLE-12) systems
- Mechanistic dissection using pharmacologic inhibition and gene knockdown with ChIP-qPCR and reporter assays
Limitations
- Preclinical models (LPS-induced injury) may not capture full complexity of human sepsis-associated ARDS
- Lack of in vivo pharmacologic modulation of BMP9/GATA3 to test therapeutic translatability
Future Directions: Evaluate pharmacologic activators or recombinant BMP9 in clinically relevant sepsis-ARDS models and explore biomarker-driven patient stratification based on BMP9/Smad1/5–YAP activity.
BMP9 protects against sepsis-induced lung injury. This research aimed to explore how BMP9 affects sepsis-associated acute respiratory distress syndrome (ARDS). Mice and MLE12 cells overexpressing BMP9 were treated with LPS to induce ARDS. Changes in ARDS-related pathological features, ferroptosis, BMP9 expression, and the Smad1/5-YAP pathway were analyzed. Regulation of BMP9 in the Smad1/5 pathway was investigated using the Smad pathway inhibitor LDN193189 and loss-of-function assays. The potential transcription factor of BMP9 was identified using the GEO and ChEA databases and validated through ChIP-qPCR, luciferase reporter assay, and functional experiments. LPS-induced mice exhibited severe lung injury, accompanied by increased inflammation, oxidative stress, and ferroptosis. Furthermore, LPS induction notably decreased BMP9, p-Smad1/5, and YAP levels in mice. BMP9 overexpression alleviated ARDS symptoms and ferroptosis while activating the Smad1/5-YAP pathway. LPS induction reduced cell viability and promoted inflammation, oxidative stress, and ferroptosis in MLE-12 cells, but BMP9 overexpression reversed these changes. Importantly, the protective effects of BMP9 overexpression were weakened by LDN193189 or by Smad1/5 or YAP knockdown. GATA3 was identified as the upstream transcription factor of BMP9, binding upstream of the BMP9 promoter region and activating its transcription. GATA3 knockdown significantly downregulated BMP9 expression in MLE-12 cells. GATA3 expression was notably decreased in ARDS models. In MLE-12 cells overexpressing BMP9, GATA3 knockdown markedly downregulated BMP9, p-Smad1/5, and YAP levels, thereby aggravating ARDS, whereas overexpression of GATA3 exerted protective effects in LPS-treated MLE-12 cells with BMP9 knockdown. In conclusion, GATA3 activates BMP9 transcription, thereby reducing inflammation and ferroptosis in sepsis-associated ARDS via the Smad1/5-YAP pathway.
2. Selective hemoadsorption of cytokines and platelet-neutrophil complexes mitigates lung microvascular hyperpermeability in an ovine acute lung injury model.
In a smoke inhalation-induced ovine ARDS model, a hemoadsorption column (NOA-001) that simultaneously removes cytokines and platelet–neutrophil complexes significantly reduced pulmonary edema and improved gas exchange versus a circuit-only control. Neutrophil capture was higher in the treatment arm, with flow cytometry indicating preferential removal of platelet–neutrophil aggregates.
Impact: This is among the first demonstrations that targeting platelet–neutrophil complexes alongside cytokines via hemoadsorption attenuates ARDS severity in vivo, opening a new therapeutic avenue beyond conventional supportive care.
Clinical Implications: If replicated in humans, selective hemoadsorption targeting PNCs and cytokines could be integrated with lung-protective ventilation and fluid management to reduce edema and improve oxygenation in severe ARDS.
Key Findings
- NOA-001 increased neutrophil capture at 4–6 hours compared with control and preferentially removed platelet–neutrophil complexes by flow cytometry.
- Treatment reduced pulmonary edema and improved gas exchange in an ovine smoke inhalation ARDS model.
- Simultaneous adsorption of cytokines and PNCs mitigated systemic inflammation and lung microvascular hyperpermeability.
Methodological Strengths
- Physiologically relevant large-animal ARDS model with concurrent control circuit
- Multiparametric assessment including flow cytometry, edema, gas exchange, and neutrophil dynamics
Limitations
- Small sample size (n=11) and potential lack of randomization/blinding details
- Preclinical findings may not translate directly to heterogeneous human ARDS etiologies
Future Directions: Conduct randomized large-animal and early-phase human trials to define efficacy, optimal timing, and biomarkers (e.g., circulating PNCs) for patient selection.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a life-threatening disease that is characterized by noncardiogenic pulmonary edema, respiratory distress, and hypoxemia, and has high mortality. Uncontrolled activation of neutrophils and formation of platelet-neutrophil complexes (PNCs) contribute significantly to its pathogenesis. In this study, we investigated whether suppression of systemic inflammation through simultaneous adsorption of inflammatory mediators, including PNCs, reduces lung invasion and offers an effective treatment strategy for ARDS. MATERIALS AND METHODS: We investigated the efficacy of a novel hemoadsorption column, NOA-001, which simultaneously removes cytokines and PNCs, in an ovine model of smoke inhalation-induced ARDS. Animals were assigned to two groups: treatment with NOA-001 (n = 6) or a control group with a blood circuit without the column (n = 5). The impact on neutrophil dynamics, lung injury, edema formation, and inflammatory markers was assessed. RESULTS: Neutrophil capture rates by NOA-001 were significantly higher at 4 and 6 h compared to controls, with a trend toward lower circulating neutrophil counts. Flow cytometry confirmed that NOA-001 predominantly removed PNCs (CD62 CONCLUSIONS: Simultaneous removal of cytokines and PNCs using NOA-001 significantly reduced ARDS severity by attenuating pulmonary edema and improving pulmonary gas exchange. These results suggest that NOA-001 may be a novel and promising therapeutic strategy for ARDS.
3. Mechanical ventilation as an independent risk factor for mortality in COVID-19-related ARDS: A secondary analysis using propensity score weighting.
In 1,724 patients with COVID-19-related ARDS at high altitude, invasive mechanical ventilation was associated with substantially higher in-hospital mortality even after covariate balancing propensity score weighting (ATE-adjusted OR 7.67). Early ventilator settings met lung-protective targets overall, but non-survivors showed rising plateau and driving pressures over five days.
Impact: By leveraging covariate balancing and IPTW, this analysis challenges the assumption that mortality differences reflect severity alone, emphasizing patient selection and non-invasive strategies in C-ARDS.
Clinical Implications: Prioritize non-invasive support when feasible, reassess indications for intubation, and rigorously track plateau/driving pressures; acknowledge residual confounding and tailor decisions to patient trajectory and resources.
Key Findings
- IMV was associated with markedly higher in-hospital mortality after IPTW adjustment (ATE-adjusted OR 7.67; 95% CI 6.20–9.48).
- Across 838 ventilated patients, initial tidal volume, plateau pressure, and driving pressure met lung-protective targets.
- Non-survivors exhibited progressive increases in plateau and driving pressures over the first five days of ventilation.
Methodological Strengths
- Large prospective cohort with covariate balancing propensity scores and IPTW to reduce confounding
- Detailed longitudinal respiratory mechanics to assess adherence to lung-protective ventilation
Limitations
- Observational design cannot eliminate residual confounding or indication bias
- Single-center high-altitude setting may limit generalizability to sea-level populations
Future Directions: Prospective multicenter studies using causal inference frameworks and competing-risk models, coupled with randomized trials of intubation thresholds or non-invasive strategies.
INTRODUCTION: The optimal role of invasive mechanical ventilation (IMV) in COVID-19-related acute respiratory distress syndrome (C-ARDS) remains uncertain. During the pandemic, many patients with ARDS were managed without IMV, creating a unique opportunity to examine whether IMV is an independent risk factor for mortality rather than a marker of disease severity alone. This study aimed to estimate the adjusted association between IMV and in-hospital mortality in patients with C-ARDS. METHODS: We performed a secondary analysis of a previously published prospective cohort of adults hospitalized with confirmed C-ARDS at a tertiary center located at high altitude (2,640 m, Bogotá, Colombia). Covariate balancing propensity scores (CBPS) were used to derive inverse probability of treatment weights (IPTW). Weighted logistic regression was then applied to estimate the average treatment effect (ATE) of IMV on in-hospital mortality. As a secondary objective, respiratory mechanics during the first 5 days of IMV were described to evaluate adherence to lung-protective ventilation. RESULTS: A total of 1,724 patients with complete data were included; median age was 68 years, 65.9% were male, and overall mortality was 44.8%. Of these, 897 patients (52.0%) required IMV. Mortality differed markedly between groups: 65% in ventilated patients vs. 22% in non-ventilated patients. After IPTW adjustment, IMV remained independently associated with higher mortality (ATE-adjusted OR 7.67; 95% CI 6.20-9.48; p < 0.001). Respiratory mechanics were available for 838 (93.4%) ventilated patients. Median tidal volume, plateau pressure, and driving pressure were initially within protective ventilation targets; however, non-survivors showed small progressive increases in plateau and driving pressures over time. CONCLUSIONS: In this propensity score-weighted cohort of patients with COVID-19-related ARDS, IMV was strongly associated with in-hospital mortality after adjustment for measured confounders. Ventilatory parameters were generally within protective ranges during the early course of ventilation, although non-survivors showed less favorable longitudinal pressure trajectories. These findings support careful patient selection, optimization of non-invasive support when feasible, and strict adherence to lung-protective ventilation strategies. Residual confounding cannot be excluded.